Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00963404 | Image-Guided Tumorboost of Bladder Cancer | completed | Phase 1 / Phase 2 | 19 | University of AarhusOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | terminated | Phase 2 | 22 | Matthew GalskyOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT02805608 |
| uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer |
| unknown |
| Phase 2 |
| 40 |
| Rigshospitalet, DenmarkOTHER |
| 1 |
| Apr 11, 2018 |
| clinicaltrials |
| NCT01259063 | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | completed | Phase 1 / Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT02845050 | Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)(JaNEO) | withdrawn | Phase 1 / Phase 2 | 0 | Ligartis GmbHINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT03427034 | Assessment of BladderLight SurvEILlance(ABSEIL) | unknown | Phase 2 / Phase 3 | 2,100 | Cambridge University Hospitals NHS Foundation TrustOTHER | 0 | Feb 9, 2018 | clinicaltrials |
| NCT01090466 | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 1 / Phase 2 | 15 | Cardiff UniversityOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00461851 | Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma | completed | Phase 2 | 17 | Yale UniversityOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT00666562 | Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT03150836 | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | withdrawn | Phase 2 | 0 | Terence Friedlander, MDOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02655081 | Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy(IMPACT) | completed | Phase 2 | 48 | University of PittsburghOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT00003452 | Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01687244 | Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | completed | Phase 2 | 40 | FKD Therapies OyINDUSTRY | 0 | Jul 24, 2017 | clinicaltrials |
| NCT00380029 | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | terminated | Phase 2 | 7 | University of MichiganOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT02307487 | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | completed | Phase 2 | 14 | UroGen Pharma Ltd.INDUSTRY | 1 | Jun 16, 2017 | clinicaltrials |
| NCT01108055 | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | completed | Phase 2 | 43 | Sandy SrinivasOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT01828736 | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma(CVH-CT02) | completed | Phase 2 | 61 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 2 | Feb 6, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01454089 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | completed | Phase 2 | 183 | Achieve Life SciencesINDUSTRY | 7 | Oct 7, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02030574 | Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin | terminated | Phase 2 | 2 | Brown UniversityOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | terminated | Phase 2 | 65 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 11, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT00406068 | Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer | completed | Phase 2 / Phase 3 | 129 | Bioniche Life Sciences Inc.INDUSTRY | 2 | Jul 28, 2016 | clinicaltrials |
| NCT00003565 | Docetaxel in Treating Patients With Solid Tumors | completed | Phase 2 | 109 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jul 14, 2016 | clinicaltrials |
| NCT02360618 | Metformin and Simvastatin Use in Bladder Cancer | unknown | Phase 2 | 44 | London Health Sciences CentreOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2016 | clinicaltrials |
| NCT00645593 | Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer | completed | Phase 2 | 89 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00506155 | Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | completed | Phase 2 | 45 | Christopher Sweeney, MBBSOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00847015 | Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02489890 | CIK in Treating Patients With Bladder Cancer | active not recruiting | Phase 2 | 1,500 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT01916109 | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | terminated | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00397488 | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00234039 | S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin | completed | Phase 2 | 58 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 8, 2016 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT01663285 | Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00585689 | Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT00714948 | Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 16, 2015 | clinicaltrials |
| NCT00479089 | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2015 | clinicaltrials |
Data updated 22 days agoSource updated May 3, 2018source: clinicaltrials